Achieve Life Sciences 관리

관리 기준 확인 0/4

Achieve Life Sciences CEO는 Rick Stewart, Aug2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 1.35M, 33.3% 로 구성됩니다. 33.3% 급여 및 66.7% 보너스(회사 주식 및 옵션 포함). 는 $ 219.79K 가치에 해당하는 회사 주식의 0.15% 직접 소유합니다. 219.79K. 경영진과 이사회의 평균 재임 기간은 각각 0.8 년과 2.7 년입니다.

주요 정보

Rick Stewart

최고 경영자

US$1.4m

총 보상

CEO 급여 비율	33.3%
CEO 임기	less than a year
CEO 소유권	0.1%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Jun 29

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Apr 04

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Mar 22

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Jun 14

We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Mar 01

Achieve Life Sciences prices stock offering at $7; shares down 2%

Dec 03

Achieve Life Sciences launches equity offering

Nov 30

CEO 보상 분석

Rick Stewart 의 보수는 Achieve Life Sciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$33m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$1m	US$450k	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	n/a	n/a	-US$44m
Dec 31 2022	US$1m	US$400k	-US$42m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$1m	US$400k	-US$33m
Sep 30 2021	n/a	n/a	-US$31m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$1m	US$474k	-US$15m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$797k	US$500k	-US$16m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$500k	-US$13m
Sep 30 2018	n/a	n/a	-US$13m
Jun 30 2018	n/a	n/a	-US$16m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$500k	US$208k	-US$11m

보상 대 시장: Rick 의 총 보상 ($USD 1.35M )은 US 시장( $USD 649.07K ).

보상과 수익: 회사가 수익성이 없는 동안 Rick 의 보상이 증가했습니다.

CEO

Rick Stewart (65 yo)

less than a year

테뉴어

US$1,350,905

보상

Dr. Richard A. B. Stewart, also known as Rick, had been an Executive Chairman at Achieve Life Sciences, Inc. since September 28, 2020 until August 2024 and serves as its Chief Executive Officer from August...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas King	Executive Chairman	1.7yrs	US$281.35k	0% $ 0
Richard A. Stewart	CEO & Executive Director	less than a year	US$1.35m	0.15% $ 219.8k
Cindy Jacobs	President	4.2yrs	US$1.20m	0.097% $ 142.5k
Jerry Wan	Principal Accounting Officer	no data	데이터 없음	0.037% $ 54.3k
Anthony Clarke	Chief Scientific Officer	7.3yrs	US$589.66k	데이터 없음
Jaime Xinos	Chief Commercial Officer	7.8yrs	데이터 없음	0.076% $ 112.8k
Mark Rubinstein	Head of Medical Affairs	less than a year	데이터 없음	데이터 없음
Craig Donnelly	Executive Vice President of CMC & Regulatory CMC	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 관리: ACHV 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas King	Executive Chairman	1.7yrs	US$281.35k	0% $ 0
Richard A. Stewart	CEO & Executive Director	7.8yrs	US$1.35m	0.15% $ 219.8k
Cindy Jacobs	President	3.7yrs	US$1.20m	0.097% $ 142.5k
Vaughn Himes	Independent Director	2.7yrs	US$195.82k	0% $ 0
Stuart Duty	Independent Director	1.7yrs	US$270.60k	0% $ 0
Thomas Sellig	Independent Director	1.7yrs	US$269.75k	0% $ 0
Bridget Martell	Independent Director	3.7yrs	US$198.75k	0% $ 0

2.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: ACHV 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Achieve Life Sciences 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. Announces CEO Changes

Achieve Life Sciences, Inc., Annual General Meeting, Jun 05, 2024

Executive Chairman exercised options and sold US$69k worth of stock

High number of new directors

Recent updates

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

New minor risk - Profitability

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Achieve Life Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement

Achieve Life Sciences, Inc. Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Achieve Life Sciences, Inc., Annual General Meeting, Jun 05, 2024

Achieve Life Sciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 17% to US$19.71

Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting

Achieve Life Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Financial position

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $60.000002 million.

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

New minor risk - Profitability

Price target decreased by 12% to US$24.71

New minor risk - Share price stability

Price target decreased by 8.1% to US$27.57

Achieve Life Sciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

New minor risk - Market cap size

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Executive Chairman exercised options and sold US$69k worth of stock

High number of new directors

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Price target increased by 14% to US$28.33

Achieve Life Sciences, Inc. Announces Last Subject Dosed in Phase 2 Orca-V1 Trial of Cytisinicline for E-Cigarette Cessation

Dialectic Capital Engages in Discussions with Achieve Life Sciences

Achieve Life Sciences, Inc. Announces That the Final Subject of the Company’s Phase 3 ORCA-3 Trial Has Completed Treatment in the Study

Achieve Life Sciences, Inc. Receives Written Notification from the Listing Qualifications Staff of the Nasdaq Stock Market

Consensus revenue estimates fall by 33%

Price target decreased to US$28.13

Achieve Life Sciences, Inc. announced that it expects to receive CAD 18.930777 million in funding

Achieve Life Sciences, Inc. Announces Early Completion of Target Enrollment in Cytisinicline E-Cigarette Cessation Trial

Achieve Life Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Consensus revenue estimates fall by 33%

Achieve Life Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine E-Cigarette Cessation

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Achieve Life Sciences Inc. Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine E-Cigarette Users

Price target increased to US$34.13

Achieve Life Sciences Announces Positive Topline Results from Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Price target decreased to US$31.50

Achieve Life Sciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Achieve Life Sciences, Inc., Annual General Meeting, May 31, 2022

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 73%

Achieve Life Sciences, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Achieve Life Sciences Announces Initiation of the Phase 3 Orca-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

Achieve Life Sciences, Inc. Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$39.50